Key result
Primary prevention ICD implantation reduces mortality in stages 1 and 2 CKD, but benefit in advanced stages is age-dependent, favored at <80 for stage 3, <75 for stage 4, and <65 for stage 5.
Why the study?
Does implantable cardioverter-defibrillator (ICD) implantation reduce mortality in patients with chronic kidney disease meeting primary prevention criteria?
Does implantable cardioverter-defibrillator (ICD) implantation reduce mortality in patients with chronic kidney disease meeting primary prevention criteria?
The mortality benefit of primary prevention ICDs in CKD patients diminishes with advancing age and worsening renal function, suggesting a need for individualized decision-making.
No takes yet. Share an insight, caveat, or question.
May inform age- and stage-stratified ICD decisions in CKD; leaves open need for randomized validation.
Amin et al. (2008) studied Chronic kidney disease (CKD). Primary prevention implantable cardioverter-defibrillator (ICD) vs. No ICD was evaluated on Mortality. Primary prevention ICD implantation reduces mortality in stages 1 and 2 CKD, but benefit in advanced stages is age-dependent, favored at <80 for stage 3, <75 for stage 4, and <65 for stage 5.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: